Revelation Biosciences reports preclinical Gemini data showing biomarker activity; Phase 1 study planned

REVELATION BIOSCIENCES, INC.

Gemini showed dose-dependent white blood cell mobilization and cytokine upregulation (IL-10, NGAL, IL-6) in healthy animal models.
Data supports Gemini as a preventative therapy for infection and acute kidney injury; key biomarkers confirmed.
Company plans to initiate a Phase 1 healthy volunteer study later this year, with full results to be published.
Second dose of Gemini demonstrated attenuated IL-6 response indicating trained immunity; two-dose regimen being evaluated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.